RECORDATI REPORTS SALES +6.2%, OPERATING INCOME +19.2% AND NET INCOME +24.3% IN THE FIRST HALF 2015 THANKS TO ITS INTERNATIONAL BUSINESS.
- Consolidated revenues € 539.1 million, +6.2%.
- EBITDA(1) € 163.9 million, +15.5%
- Operating income € 145.2 million, +19.2%.
- Net income € 103.2 million, +24.3%.
- Net financial position(2): net debt of € 139.9 million.
- Shareholders' equity € 874.9 million.
- Full year 2015 targets increased: sales of around € 1,040 million, operating income around € 270 million and net income around € 190 million.
Milan, 29 July 2015 - The Board of Directors of Recordati S.p.A. approved the Group's consolidated results for the first half 2015 prepared in accordance with International Accounting Standards and International Financial Reporting Standards (IAS/IFRS) and in particular as per IAS 34 requirements for interim reporting. These financial statements will be available today at the company's offices and on the company's website (www.recordati.com) and can also be viewed on the authorized storage system 1Info (www.1Info.it). The independent auditors' report on the consolidated condensed half-year financial statements will be available within the legal deadline at the company's offices and on the company's website (www.recordati.com) and can also be viewed on the authorized storage system 1Info (www.1Info.it).
Financial highlights
- Consolidated revenues in the first half 2015 are € 539.1 million, up by 6.2% compared to the same period of the preceding year. International sales, which represent 78.5% of total sales, grow by 10.0% while sales in Italy, at 21.5% of the total, decrease by 5.8%.
- EBITDA(1) is € 163.9 million, an increase of 15.5% over the same period of the preceding year, with a margin of 30.4% of sales thanks to gross margin improvement and the relatively low increase in operational costs.
- Operating income, at 26.9% of sales, is € 145.2 million, an increase of 19.2%.
- Net income, at 19.2% of sales, is € 103.2 million, an increase of 24.3% over the first half of 2014.
- Net financial position(2) at 30 June 2015 records a net debt of € 139.9 million, a reduction of € 46.2 million compared to that at 31 December 2014, after payment of dividends for an amount of € 49.2 million. Shareholders' equity increases to € 874.9 million.
(1) Earnings before interest, taxes, depreciation and amortization.
(2) Cash and short-term financial investments less bank overdrafts and medium/long-term loans which include the measurement at fair value of hedging derivatives (fair value hedge).
Management Comments
"The first quarter results confirm continued revenue growth and further improvement of our profitability", declared Giovanni Recordati, Chairman and CEO. "Furthermore, the group's business performance during July was in line with the first half and consequently targets for the full year 2015 were reviewed upwards of those announced on 12 February 2015. Expectations are now to achieve sales of around € 1,040 million, operating income of around € 270 million and net income of around € 190 million."
Conference call
Recordati will be hosting a conference call today 29 July 2015 at 4.00 pm Italian time (3.00 pm London time, 10.00 am New York time). The dial-in numbers are:
Italy +39 02 8020911, toll free 800 231525
UK +44 1 212818004, toll free 800 0156371
USA +1 718 7058796, toll free 855 2656958
France +33 170918704
Germany +49 65 255114450
Callers are invited to dial-in 10 minutes before conference time. If conference operator assistance is required during the connection please digit * followed by 0 or call +39 02 8061371. A recording of the conference call will be placed on the website www.recordati.com.
A set of slides which will be referred to during the call will be available on our website www.recordati.com under Investors/Company Presentations.
Recordati, established in 1926, is an international pharmaceutical group, listed on the Italian Stock Exchange (Reuters RECI.MI, Bloomberg REC IM, ISIN IT 0003828271), with a total staff of around 4,000, dedicated to the research, development, manufacturing and marketing of pharmaceuticals. Headquartered in Milan, Italy, Recordati has operations in the main European countries, in Russia, in other Central and Eastern European countries, in Turkey, in North Africa and in the United States of America. An efficient field force of medical representatives promotes a wide range of innovative pharmaceuticals, both proprietary and under license, in a number of therapeutic areas including a specialized business dedicated to treatments for rare diseases. Recordati is a partner of choice for new product licenses for its territories. Recordati is committed to the research and development of new specialties within the urogenital therapeutic area and of treatments for rare diseases. Consolidated revenue for 2014 was € 987.4 million, operating income was € 231.0 million and net income was € 161.2 million.
For further information:
Recordati website: www.recordati.com
Investor Relations Media Relations
Marianne Tatschke Studio Noris Morano
(39)0248787393 (39)0276004736, (39)0276004745
e-mail: inver@recordati.it e-mail: norismorano@studionorismorano.com
Statements contained in this release, other than historical facts, are "forward-looking statements" (as such term is defined in the Private Securities Litigation Reform Act of 1995). These statements are based on currently available information, on current best estimates, and on assumptions believed to be reasonable. This information, these estimates and assumptions may prove to be incomplete or erroneous, and involve numerous risks and uncertainties, beyond the Company's control. Hence, actual results may differ materially from those expressed or implied by such forward-looking statements. All mentions and descriptions of Recordati products are intended solely as information on the general nature of the company's activities and are not intended to indicate the advisability of administering any product in any particular instance.
RECORDATI GROUP
Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)
| INCOME STATEMENT | First half 2015 | First half 2014 | Change % |
| REVENUE | 539,060 | 507,621 | 6.2 |
| Cost of sales | (172,289) | (171,038) | 0.7 |
| GROSS PROFIT | 366,771 | 336,583 | 9.0 |
| Selling expenses | (152,503) | (145,558) | 4.8 |
| Research and development expenses | (37,911) | (40,698) | (6.8) |
| General & administrative expenses | (29,582) | (28,065) | 5.4 |
| Other income (expenses), net | (1,550) | (466) | 232.6 |
| OPERATING INCOME | 145,225 | 121,796 | 19.2 |
| Financial income (expenses), net | (8,203) | (8,772) | (6.5) |
| PRE-TAX INCOME | 137,022 | 113,024 | 21.2 |
| Provision for income taxes | (33,779) | (29,979) | 12.7 |
| NET INCOME | 103,243 | 83,045 | 24.3 |
| Attributable to: | |||
| Equity holders of the parent | 103,236 | 83,042 | 24.3 |
| Minority interests | 7 | 3 | 133.3 |
| EARNINGS PER SHARE | First half 2015 | First half 2014 | Change % |
| Basic | € 0.504 | € 0.409 | 23.2 |
| Diluted | € 0.494 | € 0.393 | 25.7 |
Earnings per share (EPS) are based on average shares outstanding during each year, 204,754,003 in 2015 and 202,930.868 in 2014, net of average treasury stock which amounted to 4,371,153 shares in 2015 and to 6,194,288 shares in 2014.
Diluted earnings per share is calculated taking into account stock options granted to employees.
| COMPOSITION OF REVENUE | First half 2015 | First half 2014 | Change % |
| Total revenue | 539,060 | 507,621 | 6.2 |
| Italy | 115,969 | 123,066 | (5.8) |
| International | 423,091 | 384,555 | 10.0 |
Pending the completion of independent audit.
RECORDATI GROUP
Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)
| INCOME STATEMENT | Second Quarter 2015 | Second Quarter 2014 | Change % |
| REVENUE | 263,314 | 247,259 | 6.5 |
| Cost of sales | (83,996) | (84,043) | (0.1) |
| GROSS PROFIT | 179,318 | 163,216 | 9.9 |
| Selling expenses | (74,525) | (70,049) | 6.4 |
| Research and development expenses | (18,019) | (19,912) | (9.5) |
| General & administrative expenses | (14,231) | (13,603) | 4.6 |
| Other income (expenses), net | (789) | (43) | n.s. |
| OPERATING INCOME | 71,754 | 59,609 | 20.4 |
| Financial income (expenses), net | (4,475) | (4,685) | (4.5) |
| PRE-TAX INCOME | 67,279 | 54,924 | 22.5 |
| Provision for income taxes | (16,004) | (14,645) | 9.3 |
| NET INCOME | 51,275 | 40,279 | 27.3 |
| Attributable to: | |||
| Equity holders of the parent | 51,272 | 40,278 | 27.3 |
| Minority interests | 3 | 1 | 200.0 |
| COMPOSITION OF REVENUE | Second Quarter 2015 | Second Quarter 2014 | Change % |
| Total revenue | 263,314 | 247,259 | 6.5 |
| Italy | 54,086 | 56,030 | (3.5) |
| International | 209,228 | 191,229 | 9.4 |
Pending the completion of independent audit.
RECORDATI GROUP
Summary of consolidated results prepared in accordance with the International Accounting Standards and International Financial Reporting Standards (IAS/IFRS)
(thousands of €)
| ASSETS | 30.6.2015 | 31.12.2014 |
| Property, plant and equipment | 101,819 | 92,273 |
| Intangible assets | 263,390 | 266,018 |
| Goodwill | 462,574 | 463,474 |
| Equity investments | 36,173 | 17,079 |
| Non-current receivables | 3,848 | 4,743 |
| Deferred tax assets | 34,389 | 33,021 |
| TOTAL NON-CURRENT ASSETS | 902,193 | 876,608 |
| Inventories | 145,194 | 141,223 |
| Trade receivables | 207,607 | 179,029 |
| Other receivables | 23,960 | 32,316 |
| Other current assets | 7,241 | 4,927 |
| Fair value of hedging derivatives (cash flow hedge) | 10,585 | 4,132 |
| Short-term financial investments, cash and cash equivalents | 186,754 | 136,990 |
| TOTAL CURRENT ASSETS | 581,341 | 498,617 |
| TOTAL ASSETS | 1,483,534 | 1,375,225 |
| EQUITY AND LIABILITIES | 30.6.2015 | 31.12.2014 |
| Share capital | 26,141 | 26,141 |
| Capital in excess of par value | 83,719 | 83,719 |
| Treasury stock | (23,817) | (30,727) |
| Hedging reserve | 4,656 | (683) |
| Translation reserve | (49,219) | (56,314) |
| Other reserves | 43,935 | 29,865 |
| Retained earnings | 686,130 | 627,240 |
| Net income for the period | 103,236 | 161,187 |
| Interim dividend | 0 | (53,080) |
| GROUP SHAREHOLDERS' EQUITY | 874,781 | 787,348 |
| Minority interest | 81 | 74 |
| SHAREHOLDERS' EQUITY | 874,862 | 787,422 |
| Loans due after one year | 286,772 | 286,202 |
| Employees' termination pay | 18,684 | 18,388 |
| Deferred tax liabilities | 29,450 | 21,553 |
| Other non-current liabilities | 3,113 | 3,102 |
| TOTAL NON-CURRENT LIABILITIES | 338,019 | 329,245 |
| Trade payables | 113,478 | 112,536 |
| Other payables | 68,301 | 64,886 |
| Tax liabilities | 17,359 | 12,541 |
| Other current liabilities | 655 | 903 |
| Provisions | 26,852 | 25,784 |
| Fair value of hedging derivatives (cash flow hedge) | 4,162 | 5,075 |
| Loans due within one year | 29,883 | 28,281 |
| Bank overdrafts | 9,963 | 8,552 |
| TOTAL CURRENT LIABILITIES | 270,653 | 258,558 |
| TOTAL EQUITY AND LIABILITIES | 1,483,534 | 1,375,225 |
Pending the completion of independent audit.
DECLARATION BY THE MANAGER RESPONSIBLE FOR PREPARING THE COMPANY'S FINANCIAL REPORTS
The manager responsible for preparing the company's financial reports Fritz Squindo declares, pursuant to paragraph 2 of Article 154-bis of the Consolidated Law on Finance, that the accounting information contained in this press release corresponds to the document results, books and accounting records.
